Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SNSE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Departure of CEO (new) — Current principal executive officer will step down upon stockholder approval, though he remains with the company as General Counsel.
- Departure of CFO (new) — Current principal financial officer will be replaced upon stockholder approval of the control-change proposals.
Sensei Biotherapeutics plans board overhaul and C-suite changes tied to control shift
Filed April 16, 2026 · Period ending April 10, 2026 · ~1 min read
Key Changes
-
high
Three directors to resign and three new directors to join, contingent on stockholders approving a preferred stock conversion that triggers a change of control under Nasdaq rules and increases authorized shares from 12.5M to 300M.
Item 5.02 verify on EDGAR → -
high
COO Anand Parikh will become CEO, replacing Christopher Gerry as principal executive officer. Gerry remains as General Counsel. Brian Stephenson will become CFO, replacing Josiah Craver as principal financial officer.
Item 5.02 verify on EDGAR → -
medium
Board adopted new severance plan offering executives 6-12 months salary for normal terminations, or enhanced packages (12-18 months salary, 1.0x-1.5x bonus, full equity acceleration) for change-of-control terminations.
Item 5.02 verify on EDGAR → -
high
All leadership changes are conditional on June 10, 2026 annual meeting approval of proposals that will dilute existing shareholders and shift company control.
8-K: Board Changes view on EDGAR →
Summary
Sensei Biotherapeutics has orchestrated a comprehensive leadership transition contingent on stockholder approval at its June 10, 2026 annual meeting.
The company is asking shareholders to approve converting preferred stock that will trigger a change of control under Nasdaq rules and dramatically increase authorized common shares from 12.5 million to 300 million—a 24-fold expansion that signals significant dilution potential.
If approved, three current directors will resign, three new directors will join, and the C-suite will be reshuffled with COO Anand Parikh becoming CEO and operations head Brian Stephenson becoming CFO. The timing is notable: the board adopted a new severance plan the same day these conditional changes were announced, offering enhanced payouts (up to 18 months salary plus 1.5x bonus and full equity acceleration) for executives terminated during a change-of-control period. This suggests the company is preparing for a significant transaction or investor involvement that could reshape ownership. Retail investors should watch the proxy materials closely to understand who is driving this change of control and at what valuation. The massive increase in authorized shares and the structured leadership transition indicate this is more than routine governance—it's likely tied to a financing or strategic transaction that existing shareholders will need to evaluate carefully before the June vote.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Three directors conditionally resigned; three new directors conditionally appointed; CEO and CFO changes planned, all contingent on stockholder approval.
Added in current filing · verify on EDGAR →
In connection with the foregoing, on April 10, 2026, the Board approved the conditional appointments of each of Stephen M. Hahn, Saira Ramasastry, and Karen Vousden (collectively, the “Incoming Directors”) to the Board, effective as of the Effective Time.
Three new directors were conditionally appointed to replace the resigning directors, effective at the same time as the resignations. The new directors will serve on various board committees including Audit, Compensation, and Nominating and Corporate Governance.
Added in current filing · verify on EDGAR →
On April 10, 2026, the Board, upon recommendation of the Compensation Committee of the Board, adopted the Sensei Biotherapeutics, Inc. Severance and Change in Control Plan (the “Severance and CIC Plan”), effective as of the same date, under which the Company’s executive officers and certain additional key employees will be eligible to receive severance payments and benefits in connection with certain qualifying terminations of their employment with the Company, subject to the conditions set forth in the Severance and CIC Plan.
The board adopted a new severance plan for executives and key employees. For terminations outside a change-in-control period, executives receive 6-12 months base salary and COBRA premiums. For terminations during a change-in-control period, they receive enhanced benefits including 12-18 months base salary paid as lump sum, bonus payments (1.0x-1.5x target), COBRA premiums, and full acceleration of time-based equity awards.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify